These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 23822538)

  • 1. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
    Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
    Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
    Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
    Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
    Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
    Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
    Mohty M; Bay JO; Faucher C; Choufi B; Bilger K; Tournilhac O; Vey N; Stoppa AM; Coso D; Chabannon C; Viens P; Maraninchi D; Blaise D
    Blood; 2003 Jul; 102(2):470-6. PubMed ID: 12649133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
    Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
    Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
    Boga C; Yeral M; Gereklioglu C; Asma S; Maytalman E; Aytan P; Kozanoglu I; Sariturk C; Ozdogu H
    Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):149-157. PubMed ID: 29474820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
    Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W;
    Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia.
    Wanquet A; Crocchiolo R; Furst S; Granata A; Faucher C; Devillier R; Harbi S; Lemarie C; Calmels B; Vey N; Weiller PJ; Chabannon C; Castagna L; Blaise D; El-Cheikh J
    Leuk Lymphoma; 2016 Oct; 57(10):2315-20. PubMed ID: 26885686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
    Russell JA; Duan Q; Chaudhry MA; Savoie ML; Balogh A; Turner AR; Larratt L; Storek J; Bahlis NJ; Brown CB; Quinlan D; Geddes M; Zacarias N; Daly A; Duggan P; Stewart DA
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):888-95. PubMed ID: 18640572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.
    Mohty M; Malard F; Blaise D; Milpied N; Furst S; Tabrizi R; Guillaume T; Vigouroux S; El-Cheikh J; Delaunay J; Le Gouill S; Moreau P; Labopin M; Chevallier P
    Cancer; 2015 Feb; 121(4):562-9. PubMed ID: 25283774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Malard F; Cahu X; Clavert A; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Mahe B; Gastinne T; Blin N; Harousseau JL; Moreau P; Miplied N; Le Gouill S; Mohty M
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1698-703. PubMed ID: 21601642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Krejci M; Brychtova Y; Doubek M; Tomiska M; Navratil M; Racil Z; Dvorakova D; Horky O; Lengerova M; Pospisilova S; Mayer J
    Neoplasma; 2011; 58(5):406-14. PubMed ID: 21744994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
    Bredeson CN; Zhang MJ; Agovi MA; Bacigalupo A; Bahlis NJ; Ballen K; Brown C; Chaudhry MA; Horowitz MM; Kurian S; Quinlan D; Muehlenbien CE; Russell JA; Savoie L; Rizzo JD; Stewart DA
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):993-1003. PubMed ID: 18721762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.